50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
NASDAQ:RVNC

Revance Therapeutics - RVNC Stock Forecast, Price & News

$25.02
-0.54 (-2.11%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.19
$25.43
50-Day Range
$14.83
$28.47
52-Week Range
$11.27
$30.00
Volume
1.56 million shs
Average Volume
2.22 million shs
Market Capitalization
$1.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.75

Revance Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
55.9% Upside
$39.00 Price Target
Short Interest
Bearish
11.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.47mentions of Revance Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$297,770 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.69) to ($3.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

101st out of 1,080 stocks

Pharmaceutical Preparations Industry

31st out of 535 stocks

RVNC stock logo

About Revance Therapeutics (NASDAQ:RVNC) Stock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Stock News Headlines

Revance Therapeutics (NASDAQ:RVNC) Raised to "Hold" at StockNews.com
Revance Therapeutics (NASDAQ:RVNC) Shares Down 4.5%
Revance Announces Proposed Public Offering of Common Stock
A Longer-Acting Botox Competitor is Coming
There's a New Way to Get Rid of Wrinkles
What 5 Analyst Ratings Have To Say About Revance Therapeutics
U.S. FDA approves Revance's wrinkle treatment
Revance Therapeutics Announces FDA Approval Of DAXXIFY - Quick Facts
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Company Calendar

Last Earnings
8/09/2022
Today
9/24/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVNC
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.00
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+58.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
6 Analysts

Profitability

Net Income
$-281,310,000.00
Net Margins
-265.04%
Pretax Margin
-265.04%

Debt

Sales & Book Value

Annual Sales
$77.80 million
Book Value
$0.95 per share

Miscellaneous

Free Float
69,378,000
Market Cap
$1.83 billion
Optionable
Optionable
Beta
0.92

Key Executives

  • Mr. Mark J. FoleyMr. Mark J. Foley (Age 57)
    CEO & Director
    Comp: $1.4M
  • Mr. Dustin S. Sjuts (Age 43)
    Pres
    Comp: $829.22k
  • Mr. Tobin C. SchilkeMr. Tobin C. Schilke (Age 47)
    CFO & Principal Accounting Officer
    Comp: $633.61k
  • Mr. Aubrey RankinMr. Aubrey Rankin (Age 46)
    Consultant
    Comp: $881.24k
  • Jessica Serra
    Head of Investor Relations & ESG
  • Mr. Dwight MoxieMr. Dwight Moxie (Age 45)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Jeanie D. Herbert
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Taryn Conway
    VP of Marketing
  • Mr. Justin Ford
    Sr. VP of HR & Head of People
  • Ms. Azita Nejad
    Sr. VP of Technical Operations













RVNC Stock - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price forecast for 2022?

6 analysts have issued 12 month price targets for Revance Therapeutics' stock. Their RVNC share price forecasts range from $24.00 to $65.00. On average, they expect the company's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 55.9% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2022?

Revance Therapeutics' stock was trading at $16.32 at the beginning of 2022. Since then, RVNC stock has increased by 53.3% and is now trading at $25.02.
View the best growth stocks for 2022 here
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) announced its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.03. The biopharmaceutical company had revenue of $28.37 million for the quarter, compared to the consensus estimate of $27.64 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 497.77% and a negative net margin of 265.04%.

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (6.03%), State Street Corp (2.43%), Jennison Associates LLC (2.41%), FMR LLC (1.66%), Rice Hall James & Associates LLC (1.49%) and Goldman Sachs Group Inc. (1.13%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dwight Moxie and Mark J Foley.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $25.02.

How much money does Revance Therapeutics make?

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $1.83 billion and generates $77.80 million in revenue each year. The biopharmaceutical company earns $-281,310,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis.

How many employees does Revance Therapeutics have?

The company employs 495 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.

This page (NASDAQ:RVNC) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.